Carregant...
AT-39 A RANDOMIZED PHASE II TRIAL OF VANDETANIB (ZD6474) IN COMBINATION WITH CARBOPLATIN VERSUS CARBOPLATIN ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA
BACKGROUND: Vandetanib is a tyrosine kinase inhibitor of VEGFR-2, EGFR, and the RET oncogene. While vandetanib has not shown significant clinical activity, preclinical experience suggests synergistic efficacy in combination with carboplatin in glioblastoma (GBM). METHODS: This randomized non-compara...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217817/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.38 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|